{"id":949848,"date":"2026-04-08T08:40:49","date_gmt":"2026-04-08T12:40:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/"},"modified":"2026-04-08T08:40:49","modified_gmt":"2026-04-08T12:40:49","slug":"gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/","title":{"rendered":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market<\/i>\n      <\/p>\n<p align=\"justify\">\n        <strong>LA JOLLA, CA, April  08, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IajQuhNacuSXi-CQPcmOvn7X04blDBESGbKse-sHQJ9eFPNI-xK3fQaPvfmMhkn3NhaJU8n_jkVXXy6CM4qqnQ==\" rel=\"nofollow\" target=\"_blank\">GRI Bio, Inc.<\/a> (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687\/2017, titled \u201c<i>Prevention and Treatment of Inflammatory Conditions<\/i>.\u201d<\/p>\n<p align=\"justify\">The allowed claims cover novel type 2 diverse NKT (\u201cdNKT\u201d) cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further expanding GRI Bio\u2019s intellectual property protection for its proprietary immunomodulatory platform. These claims support therapeutic approaches targeting immune pathways implicated in inflammatory, fibrotic and autoimmune diseases and complement the Company\u2019s existing patent portfolio. This allowance further reinforces the Company\u2019s disciplined approach to building a global intellectual property portfolio designed to support long-term exclusivity and strategic optionality.<\/p>\n<p align=\"justify\">The UAE represents a strategically significant and rapidly expanding healthcare market, serving as a gateway to the broader Middle East and North Africa (MENA) region. By securing patent protection in this region, GRI Bio strengthens its global intellectual property position for its dNKT cell agonist program and enhances its ability to support future regional partnerships, licensing opportunities and long-term commercialization strategies.<\/p>\n<p align=\"justify\">\u201cThis Notice of Allowance reflects the continued execution of our disciplined global IP strategy,\u201d said Marc Hertz, Chief Executive Officer of GRI Bio. \u201cSecuring protection in key international markets strengthens our platform and supports the advancement of our pipeline while creating additional opportunities for long-term value for shareholders.\u201d<\/p>\n<p align=\"justify\">The allowed application supports GRI Bio\u2019s broader platform focused on modulating NKT cell biology, an emerging therapeutic approach designed to regulate immune responses across a range of diseases with significant unmet need. This patent further reinforces the strength and durability of the Company\u2019s growing global intellectual property portfolio.<\/p>\n<p align=\"justify\">GRI Bio remains focused on advancing its lead program, GRI-0621, while leveraging its growing chemistry platform and library of over 500 proprietary compounds to support future pipeline expansion and potential strategic partnerships.<\/p>\n<p>\n        <b>About GRI Bio, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio\u2019s therapies are designed to target the activity of Natural Killer T (\u201cNKT\u201d) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (\u201ciNKT\u201d) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio\u2019s lead program, GRI-0621, is an RAR\u03b2\u03b3 agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (\u201cdNKT\u201d) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tferUnvBS4PjQ2bCkn5nf43vgwcxfcW1O9sqKBL2eL-uacJr63lm5-QmSq9_JutGggtXJaFm-kQhFTU1y89rGw==\" rel=\"nofollow\" target=\"_blank\">GRI@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODI1ODliODQtNGFkMy00YmE3LTlhOTctMDc1MjZmMTExODc3LTUwMDA3NTQ4OC0yMDI2LTA0LTA4LWVu\/tiny\/GRI-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687\/2017, titled \u201cPrevention and Treatment of Inflammatory Conditions.\u201d The allowed claims cover novel type 2 diverse NKT (\u201cdNKT\u201d) cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949848","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687\/2017, titled \u201cPrevention and Treatment of Inflammatory Conditions.\u201d The allowed claims cover novel type 2 diverse NKT (\u201cdNKT\u201d) cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further &hellip; Continue reading &quot;GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:40:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions\",\"datePublished\":\"2026-04-08T12:40:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/\"},\"wordCount\":595,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/\",\"name\":\"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\",\"datePublished\":\"2026-04-08T12:40:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/","og_locale":"en_US","og_type":"article","og_title":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk","og_description":"Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687\/2017, titled \u201cPrevention and Treatment of Inflammatory Conditions.\u201d The allowed claims cover novel type 2 diverse NKT (\u201cdNKT\u201d) cell agonists and related methods and compositions for the prevention and treatment of inflammatory conditions, further &hellip; Continue reading \"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T12:40:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions","datePublished":"2026-04-08T12:40:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/"},"wordCount":595,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/","name":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==","datePublished":"2026-04-08T12:40:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NTc3MiM3NTI0MDY4IzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949848"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949848\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}